Fred Hutch is at the forefront of a fundamental shift in the way cancer is treated and cured. Our researchers are developing new ways to empower a patient’s own immune system to do what it does naturally — fight disease — with potentially fewer side effects than with conventional cancer treatments.
The IIRC is dedicated to creating partnerships across Fred Hutch and jump-starting new ideas to develop the next generation of these immunotherapies for cancers and other deadly and debilitating diseases.
Advancing Our Research
Dr. Lawrence Fong is the scientific director of the IIRC. A physician-scientist, Larry has been involved with both the pre-clinical and clinical development of immunotherapies, including multiple immune checkpoint inhibitors that are now FDA-approved. In addition to his solid tumor expertise, his laboratory program has made significant contributions in understanding how immunotherapies work in patients and in identifying mechanisms of resistance that can be targeted with next-generation approaches.
A Foundation of Expertise
Fred Hutch's expertise in cell therapy, transplant immunology, tumor microenvironment, immune checkpoint regulation, immunogenomics, and therapeutic vaccines contributes to our advances in immunotherapy.
Career Opportunity
We have an opening in our two-year Immunotherapy Physician Scientist Program for an M.D. or Ph.D. who is committed to pioneering major advances in medical practice through research. Applicants should be interested in an aspect of immuno-oncology relevant to the IIRC, as well as the development of therapies that modulate the immune system.
Help Us Eliminate Cancer
Every dollar counts. Please support lifesaving research today.